June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Prevalence of Vitreomacular Interface Disease and Candidates for Ocriplasmin Treatment
Author Affiliations & Notes
  • Lucy Xu
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Omar Punjabi
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Jack Shao
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Justis Ehlers
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Sunil Srivastava
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Peter Kaiser
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2794. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lucy Xu, Omar Punjabi, Jack Shao, Justis Ehlers, Sunil Srivastava, Peter Kaiser; Prevalence of Vitreomacular Interface Disease and Candidates for Ocriplasmin Treatment. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2794.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the prevalence of different stages of vitreomacular interface (VMI) diseases including vitreomacular adhesion, vitreomacular traction (VMT) and full thickness macular holes using a novel OCT staging system. In addition, to evaluate the prevalence of patients who may qualify for treatment with ocriplasmin.

Methods: Retrospective, IRB-approved, consecutive case series of all patients with ICD-9 code of 362.54 (macular cyst, hole or pseudohole) and in whom spectral domain OCT was obtained. Patients were excluded if they had poor OCT image quality or localization. Patients were classified into the following categories: macular cyst without hole, pseudohole (partial thickness hole within an epiretinal membrane with clinical appearance of macular hole), lamellar hole (inner retinal defect without full thickness defect), vitreomacular traction without hole and full-thickness macular hole (FTMH). FTMHs were further sub-classified based on size as: minimum diameter (MD) < 250µm, 250-400µm or > 400µm. Presence of vitreous traction, epiretinal membrane, and/or cystic spaces was also quantified. The fellow eyes of patients with FTMH were studied to determine the presence of vitreomacular adhesion (stage 0 macular hole).

Results: 437 eyes of 375 patients were included in the study. 39 eyes (8.9%) had macular cyst without a hole. A lamellar hole was present in 53 eyes (12.1%) and a pseudohole in 66 eyes (15.1%). 40 eyes (9%) had VMT without a FTMH. 217 eyes (49.7%) had a FTMH. 72 eyes (16.5%) had a FTMH <250µm MD, 47 eyes (10.7%) had FTMH between 250-400µm MD and 98 eyes (22.4%) had FTMH >400µm MD. In patients with FTHM, 22 (10.1%) had a fellow eye with VMA (Stage 0 MH). In total, 84 eyes (19.2%) had traction, 166 eyes (37.9%) had ERM, and 254 eyes (58.1%) had cystic changes adjacent to the hole. 75 eyes (17.1%) with VMT, excluding FTMH >400µm, qualified for ocriplasmin therapy based on clinical studies, of which 56/75 eyes (74.7%) had no ERM and were good candidates for ocriplasmin therapy.

Conclusions: We present the prevalence of VMI disease using a novel OCT based staging system. 17.1% of all eyes with a diagnosis code 362.54 had symptomatic vitreomacular traction that qualified for ocriplasmin therapy. 74.7% of these eyes were considered good candidates for ocriplasmin therapy. 10.1% of fellow eyes with FTMH had stage 0 macular hole, indicating a need to continue screening the fellow eye.

Keywords: 586 macular holes • 550 imaging/image analysis: clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×